Arnity therapeutics
- Biotech or pharma, therapeutic R&D
ARNity Therapeutics is developing best-in-class mRNA-based active immunotherapies that instruct the body to generate its own therapeutic antibodies. This approach offers the same biological efficacy as mAbs but with the convenience and cost-efficiency of a single annual injection. Our first drug candidate, NARI-413, targets IL-4 and IL-13 for asthma patients.
Launched as a spin-off in Q2 2025, Arnity Therapeutics has assembled a comprehensive founding team and Scientific Advisory Board. GMP batch production is scheduled for 2025/2026, aiming to initiate a Phase I/IIa clinical trial in asthma in Q3 2026.
Arnity is currently raising €17 million to manufacture GMP clinical batches, fund preclinical tox studies and regulatory filings and initiate the first-in-human trial with NARI-413 for an exit in 2029.The projection suggests a potential 20x return within four years, based on standard biotech exit multiples and comparable licensing deals.
Address
SuresnesFrance
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}